



BCL-2 (Phospho-Ser70) Antibody

#11065

Catalog Number: 11065-1, 11065-2

Amount: 50 µg/50 µl, 100 µg/100 µl

Swiss-Prot No. : P10415

Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability: Store at -20°C/1 year

Immunogen: The antiserum was produced against synthesized phosphopeptide derived from human BCL-2 around the phosphorylation site of serine 70(R-T-S^P-P-L).

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.

Specificity/Sensitivity: BCL-2 (phospho-Ser70) antibody detects endogenous levels of BCL-2 only when phosphorylated at serine 70.


Reactivity: Human

Applications:

Predicted MW: 26kd

IHC:1:50~1:100 ELISA:1:10000

•



P-Peptide - +

Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using
BCL-2 (phospho-Ser70) antibody (#11065)

Background :

Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1).

References:

- Muller IM, et al. (2005) Mol Pharmacol.
Jin Z, Gao F, et al. J Biol Chem 2004 Sep 17; 279(38): 40209-19.
Kumar Biswas S, et al. Mol Cancer Ther 2004 Mar; 3(3): 327-34.
Huang ST, et al. (2002) FASEB J; 16(8): 825-32.